Document:

EX-4.5

 Exhibit 4.5 

TENTH SUPPLEMENTAL INDENTURE 
 This Tenth
Supplemental Indenture is made as of June 4, 2013 between 
  

			
		  	HONDA CANADA FINANCE INC.,
		  	a corporation incorporated under the laws of Canada,
		  	 (the “Issuer”)
  

                          
  and

		
		  	 BNY TRUST COMPANY OF CANADA
 a trust
company existing under the laws of Canada,

		  	(the “Trustee”)

 RECITALS 
 A. Pursuant to
the Trust Indenture made as of September 26, 2005 between the Issuer and the Trustee as supplemented by the First Supplemental Indenture made as of August 25, 2006, the Second Supplemental Indenture made as of December 14, 2006, the
Third Supplemental Indenture made as of May 25, 2007, the Fourth Supplemental Indenture made as of September 26, 2007, the Fifth Supplemental Indenture made as of November 30, 2007, the Sixth Supplemental Indenture made as of
May 9, 2008, the Seventh Supplemental Indenture made as of September 12, 2008, the Eighth Supplemental Indenture made as of February 21, 2012 and the Ninth Supplemental Indenture made as of December 11, 2012 (as further amended,
supplemented, modified, restated and replaced from time to time, the “Trust Indenture”), provision was made for the issuance of Additional Debentures from time to time pursuant to a supplemental indenture. 

B. The Trustee is the successor firm of CIBC Mellon Trust Company, which was the original name of the trustee under the Trust Indenture. The Trustee has
assumed the role of Trustee under the Trust Indenture. 
 C. The Issuer has authorized the issuance of one series of Debentures to be known as the
“Series 2013-1 Debentures”. 
 FOR VALUE RECEIVED, the parties agree as follows: 

SECTION 1 — INTERPRETATION 
  

	1.1	Definitions 

 In this Tenth Supplemental Indenture the following terms will have the
following meanings: 
 (1) Series 2013-1 Debentures means the Senior Unsecured Series 2013-1 Debentures to be created and issued hereunder.

 (2) Series 2013-1 Interest Payment Date means a date upon which payment of interest is due in
respect of a Series 2013-1 Debenture namely each of December 4, 2013, June 4, 2014, December 4, 2014, June 4, 2015, December 4, 2015, June 4, 2016, December 4, 2016, June 4,
2017, December 4, 2017 and the Series 2013-1 Maturity Date. 
 (3) Series 2013-1 Interest Period means in respect of a Series 2013-1
Interest Payment Date, the period commencing on and including the previous Series 2013-1 Interest Payment Date and ending on the day before such Series 2013-1 Interest Payment Date. 

(4) Series 2013-1 Maturity Date means June 4, 2018. 
  

	1.2	Meanings in Trust Indenture 

 Unless otherwise defined in this Tenth Supplemental
Indenture, all capitalized terms used in this Tenth Supplemental Indenture shall have the meanings attributed thereto in the Trust Indenture. 
  

	1.3	Interpretation 

 This Tenth Supplemental Indenture is supplemental to the Trust Indenture
and the Trust Indenture shall be read in conjunction with this Tenth Supplemental Indenture and all of the provisions of the Trust Indenture shall apply to and shall have effect in connection with this Tenth Supplemental Indenture in the same manner
as if all of the provisions of the Trust Indenture and of this Tenth Supplemental Indenture were contained in one instrument. If any terms of the Trust Indenture are inconsistent with the express terms hereof, the terms of the Trust Indenture shall
be, solely in respect of the Series 2013-1 Debentures, amended and supplemented so as to be consistent herewith. The provisions of this Tenth Supplemental Indenture are applicable only in respect of the Series 2013-1 Debentures. 

 

	1.4	Currency 

 Unless stated otherwise, all amounts herein are stated in Canadian Dollars.

 SECTION 2 — DEBENTURES 
  

	2.1	Designation, Terms, Form and Issuance of the Series 2013-1 Debentures 

  

	(1)	The Series 2013-1 Debentures shall: 

  

	 	(a)	be issued on or before June 4, 2013; 

  

	 	(b)	be designated “Senior Unsecured Series 2013-1 Debentures”; 

  

	 	(c)	bear interest from and including the date of issuance at a fixed rate equal to 2.350% per annum, payable in equal instalments semi-annually on each Series 2013-1 Interest Payment Date, the first such payment being
due on December 4, 2013; 

  
 - 2 - 

	 	(d)	be issuable as fully registered Debentures in multiples of $1,000; 

  

	 	(e)	mature on the Series 2013-1 Maturity Date; 

  

	 	(f)	provide for payment on the Series 2013-1 Maturity Date in full to each holder of a Series 2013-1 Debenture of the principal amount then outstanding thereunder together with all accrued and unpaid interest thereon and
any other amounts payable hereunder with respect thereto; 

  

	 	(g)	be substantially in the form set out in Schedule 2.1(1)(g) hereto with such appropriate insertions, deletions, substitutions and variations as may be required or permitted by this Tenth Supplemental Indenture and the
Trust Indenture or as may be required to comply with any law or the rules of any securities exchange as may be determined by the Responsible Officers executing any such Series 2013-1 Debenture; 

 

	 	(h)	bear such distinguishing letters and numbers as the Issuing and Paying Agent may approve; and 

  

	 	(i)	be limited in principal amount to $400,000,000. 

 (2) Section 4.5 of the Trust Indenture shall not apply
in respect of the Series 2013-1 Debentures but shall be replaced by the following: “Neither the Corporation nor the Issuing and Paying Agent shall be required to make transfers or exchanges of any Series 2013-1 Debenture during the following
periods each year: (i) from and including May 20 to and including June 4; and (ii) from and including November 20 to and including December 4.” 

SECTION 3 — GENERAL 
  

	3.1	Confirmation of Trust Indenture 

 The Trust Indenture as supplemented and amended by this
Tenth Supplemental Indenture, shall and does continue in full force and effect, otherwise unamended, and the Trust Indenture, as so supplemented and amended together with all the grants created thereby, is hereby ratified and confirmed. 

 

	3.2	Interest Act 

 For purposes of disclosure pursuant to the Interest Act (Canada),
the annual rates of interest provided in this Tenth Supplemental Indenture (and stated herein to be computed on the basis of a 365 day year or any other period of time less than a calendar year) are equivalent to the rates so determined multiplied
by the actual number of days in the applicable calendar year and divided by 365 or such other period of time, as the case may be. 

  
 - 3 - 

	3.3	Acceptance 

 The Trustee hereby accepts the trust in this Tenth Supplemental Indenture
declared and provided for and agrees to perform the same on the terms and conditions herein set forth. 
  

	3.4	Counterparts and Formal Date 

 This Tenth Supplemental Indenture may be executed in
several counterparts, each of which so executed shall be deemed to be an original, and such counterparts together shall constitute one and the same instrument and notwithstanding their date of execution shall be deemed to bear date as of
June 4, 2013. 
 [SIGNATURE PAGE FOLLOWS] 

  
 - 4 - 

 The parties have executed this Tenth Supplemental Indenture. 

 

			
	HONDA CANADA FINANCE INC.
		
	By:	 	 /s/ Harald Ladewig

	Name:	 	Harald Ladewig
	Title:	 	Vice-President & Treasurer
		
	By:	 	 /s/ Jean-Marc Leclerc

	Name:	 	Jean-Marc Leclerc
	Title:	 	Vice President, Compliance/Risk Officer & Secretary
	
	BNY TRUST COMPANY OF CANADA
		
	By:	 	 /s/ J. Steven Broude

	Name:	 	J. Steven Broude
	Title:	 	Vice President

  
 - 5 - 

 Schedule 2.1(1)(g) — Form of Series 2013-1 Debenture 

  
 2.1(1)(g) - 1 

	
	

	
	FURTHER TERMS AND PROVISIONS

 

	1.	At least five (5) Business Days prior to each payment date as interest on this Debenture and principal become due, the Company shall forward or cause to be forwarded by prepaid ordinary mail to the Registered
Holder at the address appearing on the register of Debentureholders maintained by Canadian Imperial Bank of Commerce (the “Issuing, Transfer and Redemption Agent”), a cheque drawn on a chartered bank in Toronto for such interest or
principal, as the case may be, payable to the registered Holder. The forwarding of such cheque shall satisfy and discharge the liability of the Company for such interest or principal to the extent of the sum represented thereby unless such cheque
shall not be paid on presentation. 

  

	2.	This Debenture is one of a series of like debentures designated as Senior Unsecured Series 2013-1 Debentures of the Company (the “Debentures”) issued pursuant to the indenture made as of September 26,
2005, the first supplemental indenture thereto dated August 25, 2006, the second supplemental indenture thereto dated December 14, 2006, the third supplemental indenture thereto dated May 25, 2007, the fourth supplemental indenture
thereto dated September 26, 2007, the fifth supplemental indenture thereto dated November 30, 2007, the sixth supplemental indenture thereto dated May 9, 2008, the seventh supplemental indenture thereto dated September 12, 2008,
the eighth supplemental indenture thereto dated February 21, 2012, the ninth supplemental indenture thereto dated December 11, 2012 and the tenth supplemental indenture thereto dated June 4, 2013 (the “Indenture”) between
the Company and BNY Trust Company of Canada (the “Trustee”). This Debenture and all other Debentures now or hereafter issued or certified under the Indenture shall rank pari passu with all other senior unsecured obligations of the Company.

  

	3.	This Debenture is issued subject to the provisions of the Indenture which is hereby referred to for a complete statement of the rights of the holders of Debentures issued thereunder and of the Company and of the Trustee
in respect thereof and of the terms and conditions upon which the Debentures are issued and held, to all of which the Registered Holder by acceptance of this Debenture assents. In the case of any conflict or inconsistency between the terms of this
Debenture and the terms of the Indenture, the terms of the Indenture shall prevail. 

  

	4.	The Indenture contains provisions dealing with the effect of default under one or more of the Debentures.

	5.	This Debenture is a direct obligation of the Company, subject to the terms and conditions of the Indenture. 

  

	6.	This Debenture shall be transferable subject to resale restrictions imposed under applicable securities laws; provided however, that no transfer of this Debenture shall be valid or effective unless: 

 

	 	(1)	it is made on the Register by the holder thereof (or by his duly appointed attorney) by written instrument in form and execution satisfactory to the Issuing, Transfer and Redemption Agent and upon compliance with such
reasonable requirements that the Issuing, Transfer and Redemption Agent or other registrar may prescribe; and 

  

	 	(2)	particulars thereof are endorsed on this Debenture by the Issuing, Transfer and Redemption Agent. 

Registered Holders should consult their own legal advisors with respect to application of resale restrictions under securities laws to which
they may be subject. 
  

	7.	The principal hereof may become due or be declared due before the Maturity Date of the Debentures, as more particularly provided in the Indenture. 

 

	8.	The Indenture contains provisions for the holding of meetings of, and the giving of notices to the Debentureholders and the rendering of Extraordinary Resolutions (as defined in the Indenture) passed by the holders of a
specified majority of the principal amount of the Debentures outstanding under the Indenture at a meeting of the Debentureholders or written instruments signed by Debentureholders may become binding upon all Debentureholders. 

 

	9.	For purposes of disclosure pursuant to the Interest Act (Canada), the annual rates of interest provided in this Debenture (and stated herein to be computed on the basis of a 365 day year or any other period of
time less than a calendar year) are equivalent to the rates so determined multiplied by the actual number of days in the applicable calendar year and divided by 365 or such period of time, as the case may be. 

 

 

 ELEVENTH SUPPLEMENTAL INDENTURE 

This Eleventh Supplemental Indenture is made as of September 3, 2013 between 
  

			
		  	HONDA CANADA FINANCE INC.,
		  	a corporation incorporated under the laws of Canada,
		  	 (the “Issuer”)
  

                          
  and

		
		  	 BNY TRUST COMPANY OF CANADA
 a trust
company existing under the laws of Canada,

		  	(the “Trustee”)

 RECITALS 
 A. Pursuant to
the Trust Indenture made as of September 26, 2005 between the Issuer and the Trustee as supplemented by the First Supplemental Indenture made as of August 25, 2006, the Second Supplemental Indenture made as of December 14, 2006, the
Third Supplemental Indenture made as of May 25, 2007, the Fourth Supplemental Indenture made as of September 26, 2007, the Fifth Supplemental Indenture made as of November 30, 2007, the Sixth Supplemental Indenture made as of
May 9, 2008, the Seventh Supplemental Indenture made as of September 12, 2008, the Eighth Supplemental Indenture made as of February 21, 2012, the Ninth Supplemental Indenture made as of December 11, 2012 and the Tenth
Supplemental Indenture made as of June 4, 2013 (as further amended, supplemented, modified, restated and replaced from time to time, the “Trust Indenture”), provision was made for the issuance of Additional Debentures from time
to time pursuant to a supplemental indenture. 
 B. The Trustee is the successor firm of CIBC Mellon Trust Company, which was the original name of the
trustee under the Trust Indenture. The Trustee has assumed the role of Trustee under the Trust Indenture. 
 C. The Issuer has authorized the issuance of
two series of Debentures to be known as the “Series 2013-2 Debentures” and the “Series 2013-3 Debentures”. 
 FOR VALUE RECEIVED,
the parties agree as follows: 
 SECTION 1 — INTERPRETATION 
  

	1.1	Definitions 

 In this Eleventh Supplemental Indenture the following terms will have the
following meanings: 
 (1) Series 2013-2 Debentures means the Senior Unsecured Series 2013-2 Debentures to be created and issued hereunder.

 (2) Series 2013-3 Debentures means the Senior Unsecured Series 2013-3 Debentures to be created and
issued hereunder. 
 (3) Series 2013-2 Interest Payment Date means a date upon which payment of interest is due in respect of a Series 2013-2
Debenture namely each of December 3, 2013, March 3, 2014, June 3, 2014, September 3, 2014, December 3, 2014, March 3, 2015, June 3, 2015, September 3, 2015 and the Series 2013-2 Maturity Date. 

(4) Series 2013-3 Interest Payment Date means a date upon which payment of interest is due in respect of a Series 2013-3 Debenture namely each
of December 3, 2013, March 3, 2014, June 3, 2014, September 3, 2014, December 3, 2014, March 3, 2015, June 3, 2015, September 3, 2015, December 3, 2015, March 3, 2016, June 3, 2016, September 3, 2016, December 3, 2016, March 3, 2017,
June 3, 2017, September 3, 2017, December 3, 2017, March 3, 2018, June 3, 2018, September 3, 2018 and the Series 2013-3 Maturity Date. 
 (5)
Series 2013-2 Interest Period means in respect of a Series 2013-2 Interest Payment Date, the period commencing on and including the previous Series 2013-2 Interest Payment Date and ending on the day before such Series 2013-2 Interest
Payment Date. 
 (6) Series 2013-3 Interest Period means in respect of a Series 2013-3 Interest Payment Date, the period commencing on and
including the previous Series 2013-3 Interest Payment Date and ending on the day before such Series 2013-3 Interest Payment Date. 
 (7) Series 2013-2
Maturity Date means December 3, 2015. 
 (8) Series 2013-3 Maturity Date means December 3, 2018. 

 

	1.2	Meanings in Trust Indenture 

 Unless otherwise defined in this Eleventh Supplemental
Indenture, all capitalized terms used in this Eleventh Supplemental Indenture shall have the meanings attributed thereto in the Trust Indenture. 
  

	1.3	Interpretation 

 This Eleventh Supplemental Indenture is supplemental to the Trust
Indenture and the Trust Indenture shall be read in conjunction with this Eleventh Supplemental Indenture and all of the provisions of the Trust Indenture shall apply to and shall have effect in connection with this Eleventh Supplemental Indenture in
the same manner as if all of the provisions of the Trust Indenture and of this Eleventh Supplemental Indenture were contained in one instrument. If any terms of the Trust Indenture are inconsistent with the express terms hereof, the terms of the
Trust Indenture shall be, solely in respect of the Series 2013-2 Debentures and the Series 2013-3 Debentures, amended and supplemented so as to be consistent herewith. The provisions of this Eleventh Supplemental Indenture are applicable only in
respect of the Series 2013-2 Debentures and the Series 2013-3 Debentures. 

  
 -2- 

	1.4	Currency 

 Unless stated otherwise, all amounts herein are stated in Canadian Dollars.

 SECTION 2 — DEBENTURES 
  

	2.1	Designation, Terms, Form and Issuance of the Series 2013-2 Debentures and the 2013-3 Debentures 

  

	(1)	The Series 2013-2 Debentures shall: 

  

	 	(a)	be issued on or before September 3, 2013; 

  

	 	(b)	be designated “Senior Unsecured Series 2013-2 Debentures”; 

  

	 	(c)	bear interest from and including the date of issuance at a rate equal to the Floating Rate plus 0.42%, payable quarterly in arrears on each Series 2013-2 Interest Payment Date, the first such payment being due on
December 3, 2013; 

  

	 	(d)	be issuable as fully registered Debentures in multiples of $1,000; 

  

	 	(e)	mature on the Series 2013-2 Maturity Date; 

  

	 	(f)	provide for payment on the Series 2013-2 Maturity Date in full to each holder of a Series 2013-2 Debenture of the principal amount then outstanding thereunder together with all accrued and unpaid interest thereon and
any other amounts payable hereunder with respect thereto; 

  

	 	(g)	be substantially in the form set out in Schedule 2.1(1)(g) hereto with such appropriate insertions, deletions, substitutions and variations as may be required or permitted by this Eleventh Supplemental Indenture and the
Trust Indenture or as may be required to comply with any law or the rules of any securities exchange as may be determined by the Responsible Officers executing any such Series 2013-2 Debenture; 

 

	 	(h)	bear such distinguishing letters and numbers as the Issuing and Paying Agent may approve; and 

  

	 	(i)	be limited in principal amount to $300,000,000. 

  

	(2)	The Series 2013-3 Debentures shall: 

  

	 	(a)	be issued on or before September 3, 2013; 

  

	 	(b)	be designated “Senior Unsecured Series 2013-3 Debentures”; 

  
 -3- 

	 	(c)	bear interest from and including the date of issuance at a rate equal to the Floating Rate plus 0.65%, payable quarterly in arrears on each Series 2013-3 Interest Payment Date, the first such payment being due on
December 3, 2013; 

  

	 	(d)	be issuable as fully registered Debentures in multiples of $1,000; 

  

	 	(e)	mature on the Series 2013-3 Maturity Date; 

  

	 	(f)	provide for payment on the Series 2013-3 Maturity Date in full to each holder of a Series 2013-3 Debenture of the principal amount then outstanding thereunder together with all accrued and unpaid interest thereon and
any other amounts payable hereunder with respect thereto; 

  

	 	(g)	be substantially in the form set out in Schedule 2.1(2)(g) hereto with such appropriate insertions, deletions, substitutions and variations as may be required or permitted by this Eleventh Supplemental Indenture and the
Trust Indenture or as may be required to comply with any law or the rules of any securities exchange as may be determined by the Responsible Officers executing any such Series 2013-3 Debenture; 

 

	 	(h)	bear such distinguishing letters and numbers as the Issuing and Paying Agent may approve; and 

  

	 	(i)	be limited in principal amount to $250,000,000. 

 (3) Section 4.5 of the Trust Indenture shall not apply
in respect of the Series 2013-2 Debentures and the Series 2013-3 Debentures but shall be replaced by the following: “Neither the Corporation nor the Issuing and Paying Agent shall be required to make transfers or exchanges of any Series 2013-2
Debenture or any Series 2013-3 Debenture during the following periods each year: 
  

	 	(a)	in the case of Series 2013-2 Debentures (i) from and including February 17 to and including March 3; (ii) from and including May 20 to and including June 3; (iii) from and including
August 20 to and including September 3; and (iv) from and including November 19 to and including December 3, and 

  

	 	(b)	in the case of Series 2013-3 Debentures (i) from and including February 17 to and including March 3; (ii) from and including May 20 to and including June 3; (iii) from and including
August 20 to and including September 3; and (iv) from and including November 19 to and including December 3.” 

  
 -4- 

 SECTION 3 — GENERAL 
  

	3.1	Confirmation of Trust Indenture 

 The Trust Indenture as supplemented and amended by this
Eleventh Supplemental Indenture, shall and does continue in full force and effect, otherwise unamended, and the Trust Indenture, as so supplemented and amended together with all the grants created thereby, is hereby ratified and confirmed. 

 

	3.2	Interest Act 

 For purposes of disclosure pursuant to the Interest Act (Canada),
the annual rates of interest provided in this Eleventh Supplemental Indenture (and stated herein to be computed on the basis of a 365 day year or any other period of time less than a calendar year) are equivalent to the rates so determined
multiplied by the actual number of days in the applicable calendar year and divided by 365 or such other period of time, as the case may be. 
  

	3.3	Acceptance 

 The Trustee hereby accepts the trust in this Eleventh Supplemental Indenture
declared and provided for and agrees to perform the same on the terms and conditions herein set forth. 
  

	3.4	Counterparts and Formal Date 

 This Eleventh Supplemental Indenture may be executed in
several counterparts, each of which so executed shall be deemed to be an original, and such counterparts together shall constitute one and the same instrument and notwithstanding their date of execution shall be deemed to bear date as of
September 3, 2013. 
 [SIGNATURE PAGE FOLLOWS] 

  
 -5- 

 The parties have executed this Eleventh Supplemental Indenture. 

 

			
	HONDA CANADA FINANCE INC.
		
	By:	 	 /s/ Harald Ladewig

	Name:	 	Harald Ladewig
	Title:	 	Vice President - Treasurer & Compliance Officer
		
	By:	 	 /s/ Jean-Marc Leclerc

	Name:	 	Jean-Marc Leclerc
	Title:	 	Vice President - Secretary & Risk Officer
	
	BNY TRUST COMPANY OF CANADA
		
	By:	 	 /s/ J. Steven Broude

	Name:	 	J. Steven Broude
	Title:	 	Vice President

  
 -6- 

 FURTHER TERMS AND PROVISIONS 

Schedule 2.1(1)(g) — Form of Series 2013-2 Debenture 

  
 2.1(1)(g) - 1 

 FURTHER TERMS AND PROVISIONS 

 

	
	

	
	FURTHER TERMS AND PROVISIONS

 

 1. At least five (5) Business Days prior to each payment date as interest on this Debenture and principal
become due, the Company shall forward or cause to be forwarded by prepaid ordinary mail to the Registered Holder at the address appearing on the register of Debentureholders maintained by Canadian Imperial Bank of Commerce (the “Issuing,
Transfer and Redemption Agent”), a cheque drawn on a chartered bank in Toronto for such interest or principal, as the case may be, payable to the registered Holder. The forwarding of such cheque shall satisfy and discharge the liability of the
Company for such interest or principal to the extent of the sum represented thereby unless such cheque shall not be paid on presentation. 
 2. This
Debenture is one of a series of like debentures designated as Senior Unsecured Series 2013-1 Debentures of the Company (the “Debentures”) issued pursuant to the indenture made as of September 26, 2005, the first supplemental indenture
thereto dated August 25, 2006, the second supplemental indenture thereto dated December 14, 2006, the third supplemental indenture thereto dated May 25, 2007, the fourth supplemental indenture thereto dated September 26, 2007,
the fifth supplemental indenture thereto dated November 30, 2007, the sixth supplemental indenture thereto dated May 9, 2008, the seventh supplemental indenture thereto dated September 12, 2008, the eighth supplemental indenture
thereto dated February 21, 2012, the ninth supplemental indenture thereto dated December 11, 2012 and the tenth supplemental indenture thereto dated June 4, 2013 and the eleventh supplemental indenture dated September 3, 2013
(the “Indenture”) between the Company and BNY Trust Company of Canada (the “Trustee”). This Debenture and all other Debentures now or hereafter issued or certified under the Indenture shall rank pari passu with all other senior
unsecured obligations of the Company. 
 3. This Debenture is issued subject to the provisions of the Indenture which is hereby referred to for a complete
statement of the rights of the holders of Debentures issued thereunder and of the Company and of the Trustee in respect thereof and of the terms and conditions upon which the Debentures are issued and held, to all of which the Registered Holder by
acceptance of this Debenture assents. In the case of any conflict or inconsistency between the terms of this Debenture and the terms of the Indenture, the terms of the Indenture shall prevail.

 4. The Indenture contains provisions dealing with the effect of default under one or more of the Debentures.

 5. This Debenture is a direct obligation of the Company, subject to the terms and conditions of the Indenture. 

6. This Debenture shall be transferable subject to resale restrictions imposed under applicable securities laws; provided however, that no transfer of this
Debenture shall be valid or effective unless: 
 (1) it is made on the Register by the holder thereof (or by his duly appointed attorney) by written
instrument in form and execution satisfactory to the Issuing, Transfer and Redemption Agent and upon compliance with such reasonable requirements that the Issuing, Transfer and Redemption Agent or other registrar may prescribe; and 

(2) particulars thereof are endorsed on this Debenture by the Issuing, Transfer and Redemption Agent. 

Registered Holders should consult their own legal advisors with respect to application of resale restrictions under securities laws to which they may be
subject. 
 7. The principal hereof may become due or be declared due before the Maturity Date of the Debentures, as more particularly provided in the
Indenture. 
 8. The Indenture contains provisions for the holding of meetings of, and the giving of notices to the Debentureholders and the rendering of
Extraordinary Resolutions (as defined in the Indenture) passed by the holders of a specified majority of the principal amount of the Debentures outstanding under the Indenture at a meeting of the Debentureholders or written instruments signed by
Debentureholders may become binding upon all Debentureholders. 
 9. For purposes of disclosure pursuant to the Interest Act (Canada), the annual
rates of interest provided in this Debenture (and stated herein to be computed on the basis of a 365 day year or any other period of time less than a calendar year) are equivalent to the rates so determined multiplied by the actual number of days in
the applicable calendar year and divided by 365 or such period of time, as the case may be. 

 

 Schedule 2.1(2)(g) — Form of Series 2013-3 Debenture 

  
 2.1(2)(g) - 1 

	
	

	
	

 

	1.	At least five (5) Business Days prior to each payment date as interest on this Debenture and principal become due, the Company shall forward or cause to be forwarded by prepaid ordinary mail to the Registered
Holder at the address appearing on the register of Debentureholders maintained by Canadian Imperial Bank of Commerce (the “Issuing, Transfer and Redemption Agent”), a cheque drawn on a chartered bank in Toronto for such interest or
principal, as the case may be, payable to the registered Holder. The forwarding of such cheque shall satisfy and discharge the liability of the Company for such interest or principal to the extent of the sum represented thereby unless such cheque
shall not be paid on presentation. 

  

	2.	This Debenture is one of a series of like debentures designated as Senior Unsecured Series 2013-1 Debentures of the Company (the “Debentures”) issued pursuant to the indenture made as of September 26,
2005, the first supplemental indenture thereto dated August 25, 2006, the second supplemental indenture thereto dated December 14, 2006, the third supplemental indenture thereto dated May 25, 2007, the fourth supplemental indenture
thereto dated September 26, 2007, the fifth supplemental indenture thereto dated November 30, 2007, the sixth supplemental indenture thereto dated May 9, 2008, the seventh supplemental indenture thereto dated September 12, 2008,
the eighth supplemental indenture thereto dated February 21, 2012, the ninth supplemental indenture thereto dated December 11, 2012 and the tenth supplemental indenture thereto dated June 4, 2013 and the eleventh supplemental
indenture dated September 3, 2013 (the “Indenture”) between the Company and BNY Trust Company of Canada (the “Trustee”). This Debenture and all other Debentures now or hereafter issued or certified under the Indenture shall
rank pari passu with all other senior unsecured obligations of the Company. 

  

	3.	This Debenture is issued subject to the provisions of the Indenture which is hereby referred to for a complete statement of the rights of the holders of Debentures issued thereunder and of the Company and of the Trustee
in respect thereof and of the terms and conditions upon which the Debentures are issued and held, to all of which the Registered Holder by acceptance of this Debenture assents. In the case of any conflict or inconsistency between the terms of this
Debenture and the terms of the Indenture, the terms of the Indenture shall prevail. 

 

	4.	The Indenture contains provisions dealing with the effect of default under one or more of the Debentures. 

  

	5.	This Debenture is a direct obligation of the Company, subject to the terms and conditions of the Indenture. 

  

	6.	This Debenture shall be transferable subject to resale restrictions imposed under applicable securities laws; provided however, that no transfer of this Debenture shall be valid or effective unless: 

 

	 	(1)	it is made on the Register by the holder thereof (or by his duly appointed attorney) by written instrument in form and execution satisfactory to the Issuing, Transfer and Redemption Agent and upon compliance with such
reasonable requirements that the Issuing, Transfer and Redemption Agent or other registrar may prescribe; and 

  

	 	(2)	particulars thereof are endorsed on this Debenture by the Issuing, Transfer and Redemption Agent. 

Registered Holders should consult their own legal advisors with respect to application of resale restrictions under securities laws to which
they may be subject. 
  

	7.	The principal hereof may become due or be declared due before the Maturity Date of the Debentures, as more particularly provided in the Indenture. 

 

	8.	The Indenture contains provisions for the holding of meetings of, and the giving of notices to the Debentureholders and the rendering of Extraordinary Resolutions (as defined in the Indenture) passed by the holders of a
specified majority of the principal amount of the Debentures outstanding under the Indenture at a meeting of the Debentureholders or written instruments signed by Debentureholders may become binding upon all Debentureholders. 

 

	9.	For purposes of disclosure pursuant to the Interest Act (Canada), the annual rates of interest provided in this Debenture (and stated herein to be computed on the basis of a 365 day year or any other period of
time less than a calendar year) are equivalent to the rates so determined multiplied by the actual number of days in the applicable calendar year and divided by 365 or such period of time, as the case may be.EX-10.1

 Exhibit 10.1 

SECOND AMENDMENT 
 TO

 LOAN AND SECURITY AGREEMENT 

THIS SECOND AMENDMENT to LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of September 23, 2013, by and
among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, the “Collateral
Agent”), the Lenders listed on Schedule 1.1 thereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender, SILICON VALLEY BANK, a California corporation with an office located at 3003 Tasman
Drive, Santa Clara, California 95054 (“SVB”) and HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation with an office located at 312 Farmington Avenue, Farmington, Connecticut 06032 (“HRZN;” together with
Oxford and SVB, each a “Lender” and collectively, the “Lenders”), and SUNESIS PHARMACEUTICALS, INC., a Delaware corporation with offices located at 395 Oyster Point Boulevard, Suite 400, South San Francisco,
California 94080 (“Borrower”). 
 RECITALS 

A. Collateral Agent, Borrower and the Lenders have entered into that certain Loan and Security Agreement dated as of October 18,
2011 (as the same may from time to time be amended, modified, supplemented or restated, including but without limitation by that certain First Amendment to Loan and Security Agreement dated as of March 29, 2012, the “Loan
Agreement”). 
 B. The Lenders extended credit to Borrower for the purposes permitted in the Loan Agreement. 

C. Borrower has requested that Collateral Agent and the Lenders (i) consent to Borrower’s formation of two foreign
subsidiaries and (ii) make certain revisions to the Loan Agreement as more fully set forth herein. 
 D. Collateral Agent and
the Lenders have agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below. 

AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the
receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows: 
 1.
Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement. 

2. Amendments to Loan Agreement. 

2.1 Section 2.5 (Fees). New Section 2.5(e) hereby is added to the Loan Agreement in its entirety as follows: 

“(e) Second Amendment Fee. On the Second Amendment Effective Date, a fully earned, non-refundable fee of Fifty
Thousand Dollars ($50,000.00) (the “Second Amendment Fee”) to be shared between the Lenders pursuant to their respective Commitment Percentages, of which (i) Twenty Five Thousand Dollars ($25,000.00) shall be payable on the
Second Amendment Effective Date and (ii) Twenty Five Thousand Dollars ($25,000.00) shall be payable upon Borrower achieving the Equity Event; provided, however, that if Borrower does not achieve the Equity Event, then in lieu of the second
Twenty Five Thousand Dollar ($25,000.00) payment, Borrower shall issue to the Lenders warrants to purchase stock in the amount of Twenty Five Thousand Dollars ($25,000.00) in form and substance of Annex II attached hereto.” 

 2.2 Section 4.3 (Pledge of Collateral). New Section 4.3 hereby is added to the
Loan Agreement in its entirety as follows: 
 “4.3 Pledge of Collateral. Borrower hereby pledges, assigns and
grants to Collateral Agent, for the ratable benefit of the Lenders, a security interest in the Shares, together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights to subscribe for
securities declared or granted in connection therewith, and all other cash and noncash proceeds of the foregoing, as security for the performance of the Obligations. On the Effective Date, or, to the extent not certificated as of the Effective Date,
within ten (10) days of the certification of any Shares, the certificate or certificates for the Shares will be delivered to Collateral Agent, accompanied by an instrument of assignment duly executed in blank by Borrower. To the extent required
by the terms and conditions governing the Shares, Borrower shall cause the books of each entity whose Shares are part of the Collateral and any transfer agent to reflect the pledge of the Shares. Upon the occurrence and during the continuance of an
Event of Default hereunder, Collateral Agent may effect the transfer of any securities included in the Collateral (including but not limited to the Shares) into the name of Collateral Agent and cause new (as applicable) certificates representing
such securities to be issued in the name of Collateral Agent or its transferee. Borrower will execute and deliver such documents, and take or cause to be taken such actions, as Collateral Agent may reasonably request to perfect or continue the
perfection of Collateral Agent’s security interest in the Shares. Unless an Event of Default shall have occurred and be continuing, Borrower shall be entitled to exercise any voting rights with respect to the Shares and to give consents,
waivers and ratifications in respect thereof, provided that no vote shall be cast or consent, waiver or ratification given or action taken which would be inconsistent with any of the terms of this Agreement or which would constitute or create any
violation of any of such terms. All such rights to vote and give consents, waivers and ratifications shall terminate upon the occurrence and continuance of an Event of Default.” 

2.3 Section 5.10 (Shares). New Section 5.10 hereby is added to the Loan Agreement in its entirety as follows: 

“5.10 Shares. Borrower has full power and authority to create a first lien on the Shares and no disability or
contractual obligation exists that would prohibit Borrower from pledging the Shares pursuant to this Agreement. To Borrower’s knowledge, there are no subscriptions, warrants, rights of first refusal or other restrictions on transfer relative
to, or options exercisable with respect to the Shares. The Shares have been and will be duly authorized and validly issued, and are fully paid and non-assessable. To Borrower’s knowledge, the Shares are not the subject of any present or
threatened suit, action, arbitration, administrative or other proceeding, and Borrower knows of no reasonable grounds for the institution of any such proceedings.” 

2.4 Section 7.1 (Dispositions). New subsection (f) hereby is added to the end of Section 7.1 of the Loan Agreement in
its entirety as follows: 
 “(f) an exclusive license of Borrower’s commercial rights (outside of the United
States) of Vosaroxin to Sunesis International pursuant to the Letter Agreement and the Resource Pooling Arrangement.” 
 2.5 New
Section 7.12 (Foreign Cash Assets). New Section 7.12 hereby is added to the Loan Agreement in its entirety as follows: 

“7.12 Foreign Cash Assets. Permit Borrower and its Subsidiaries to maintain cash assets outside the United States
(i) at any time through December 31, 2013, to exceed twenty five percent (25%) of Borrower’s and its Subsidiaries’ total cash assets and (ii) commencing as of January 1, 2014, to exceed twenty percent (20%) of
Borrower’s and its Subsidiaries’ total cash assets.” 

  
 2 

 2.6 Section 14 (Definitions). Effective from and after the Second Amendment Effective
Date, the following terms and their definitions set forth in Section 14.1 of the Loan Agreement hereby are added or amended in their entirety and/or replaced with the following: 

“Bermuda Share Pledge Documents” means those certain share pledge agreements by Sunesis Bermuda and Sunesis
International in favor of Collateral Agent, for the ratable benefit of the Lenders, in form and substance reasonably satisfactory to Collateral Agent and the Lenders, and any other documents, instruments, and undertakings necessary and reasonably
required by Collateral Agent and the Lenders to be executed in connection therewith. 
 “Equity Event” means
Borrower’s receipt after the Second Amendment Effective Date and by no later than December 31, 2013 of gross cash proceeds of at least Ten Million Dollars ($10,000,000.00) from the sale or issuance of Borrower’s equity securities .

 “Letter Agreement” means that certain Letter Agreement from Borrower to Sunesis International dated as of
July 22, 2013, as in effect on the Second Amendment Effective Date. 
 “Loan Documents” are,
collectively, this Agreement, the Warrants, the Bermuda Share Pledge Documents, the Perfection Certificates, each Compliance Certificate, the Post Closing Letter, the IP Agreement, any subordination agreements, any note, or notes or guaranties
executed by Borrower, and any other present or future agreement entered into by Borrower for the benefit of Lenders and Collateral Agent in connection with this Agreement, all as amended, restated, or otherwise modified. 

“Resource Pooling Arrangement” means that certain Resource Pooling Arrangement by and between Borrower and
Sunesis International dated as of July 1, 2013, as in effect on the Second Amendment Effective Date. 
 “Second
Amendment Effective Date” means September 23, 2013. 
 “Shares” means (i) in the case of
any entity organized under the laws of the United States or any territory thereof (a “U.S. Subsidiary”), one hundred percent (100%) of the issued and outstanding capital stock, membership units or other securities owned or held of
record by Borrower, in any Subsidiary; and provided that, (ii) in the case of any entity which is not an entity organized under the laws of the United States or any state or territory thereof and which is owned directly by (a) Borrower or
(b) any U.S. Subsidiary of Borrower (in each case of (a) or (b) a “First Tier Foreign Subsidiary”), sixty-five percent (65%) of the issued and outstanding capital stock, membership units or other securities owned or
held of record by Borrower in such First Tier Foreign Subsidiary and (iii) for clarity’s sake, with respect to Sunesis Bermuda and Sunesis International, “Shares” shall mean sixty-five percent (65%) of the issued and
outstanding capital stock and preferred interests owned or held of record by Borrower in such First Tier Foreign Subsidiaries. 

“Sunesis Bermuda” means Sunesis Pharmaceuticals (Bermuda) Ltd, a 100% owned First Tier Foreign Subsidiary of
Borrower formed under the laws of Bermuda. 
 “Sunesis International” means Sunesis Pharmaceuticals
International LP, a limited partnership formed by Borrower and Sunesis Bermuda under the laws of Bermuda, and thereby a First Tier Foreign Subsidiary of the Borrower. 

2.7 Section 14 (Definitions). New subsection (f) hereby is added to the defined term “Permitted Investments”
in Section 14.1 of the Loan Agreement in its entirety as follows: 
 “(f) a one-time investment not to exceed Ten
Million Dollars ($10,000,000.00) in the aggregate to Sunesis Bermuda and Sunesis International into an account maintained at SVB, which shall not be subject to a Control Agreement.” 

  
 3 

 2.8 New Annex II attached hereto hereby is added to the Loan Agreement. 

2.9 Collateral Agent and Lenders hereby consent to Borrower’s formation of subsidiaries (i) Sunesis Bermuda and
(ii) Sunesis International. 
 3. Limitation of Amendments. 

3.1 The amendments set forth in Section 2, above, are effective for the purposes set forth herein and shall be limited precisely
as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent may now have or may
have in the future under or in connection with any Loan Document. 
 3.2 This Amendment shall be construed in connection with and as
part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. 

4. Representations and Warranties. To induce Collateral Agent and the Lenders to enter into this Amendment, Borrower hereby represents
and warrants to Collateral Agent as follows: 
 4.1 Immediately after giving effect to this Amendment, (a) the representations
and warranties contained in the Loan Documents (as such may be modified by the updated Perfection Certificates delivered to Collateral Agent on or around the date hereof) are true, accurate and complete in all material respects as of the date hereof
(except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing; 

4.2 Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement,
as amended by this Amendment; 
 4.3 The organizational documents of Borrower delivered to Collateral Agent in connection with the
execution of the Loan Agreement remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect; 

4.4 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, have been duly authorized; 
 4.5 The execution and delivery by Borrower of this Amendment
and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a
Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower; 

4.6 The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan
Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision
thereof, binding on either Borrower, except as already has been obtained or made; and 
 4.7 This Amendment has been duly executed
and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other
similar laws of general application and equitable principles relating to or affecting creditors’ rights. 

  
 4 

 5. Counterparts. This Amendment may be executed in any number of counterparts and all of
such counterparts taken together shall be deemed to constitute one and the same instrument. 
 6. Effectiveness. This Amendment shall
be deemed effective upon (a) the due execution and delivery to Collateral Agent of (i) this Amendment, by each party hereto; (ii) the Bermuda Share Pledge Documents; (iii) that certain Consent to Security Interest and Assignment
of Resource Pooling Arrangement and (iii) updated Borrowing Resolutions for Borrower, in the form attached hereto; (b) payment by Borrower of the first Twenty Five Thousand Dollars ($25,000.00) of the Second Amendment Fee and
(c) payment by Borrower of all unpaid Lender Expenses incurred to date, which may be debited from any of Borrower’s accounts. 

[Balance of Page Intentionally Left Blank] 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have
caused this Amendment to be duly executed and delivered as of the date first written above. 
  

									
	BORROWER:	 		 		 	
				
	SUNESIS PHARMACEUTICALS, INC.	 		 		 	
					
	By	 	 /s/ Eric Bjerkholt
	 		 		 	
	Name:	 	 Eric Bjerkholt
	 		 		 	
	Title:	 	 EVP Corp Dev and Finance, CFO
	 		 		 	
				
	COLLATERAL AGENT:	 		 		 	
				
	OXFORD FINANCE LLC	 		 		 	
					
	By	 	 /s/ Mark Davis
	 		 		 	
	Name:	 	 Mark Davis
	 		 		 	
	Title:	 	 Vice President – Finance, Secretary & Treasurer
	 		 		 	
			
	LENDER:	 		 	LENDER:
			
	 OXFORD FINANCE FUNDING I, LLC
 By:
Oxford Finance LLC, as servicer
	 		 	HORIZON TECHNOLOGY FINANCE CORPORATION
					
	By	 	 /s/ Mark Davis
	 		 	By	 	 /s/ Robert D. Pomeroy, Jr.

	Name:	 	 Mark Davis
	 		 	Name:	 	 Robert D. Pomeroy Jr.

	Title:	 	 Vice President – Finance, Secretary & Treasurer
	 		 	Title:	 	 Chief Executive Officer

			
	LENDER:	 		 	LENDER:
			
	OXFORD FINANCE FUNDING TRUST 2012-1	 		 	SILICON VALLEY BANK
	By: Oxford Finance LLC, as servicer	 		 		 	
					
	By	 	 /s/ Mark Davis
	 		 	By	 	 /s/ David M. Sabow

	Name:	 	 Mark Davis
	 		 	Name:	 	 David M. Sabow

	Title:	 	 Vice President – Finance, Secretary & Treasurer
	 		 	Title:	 	 Managing Director

 ANNEX II 

Form of Warrant 
 [see
attached] 

 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT
AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

WARRANT TO PURCHASE STOCK 
  

			
	Company:	  	SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”)
		
	Number of Shares:	  	[$15,000/Warrant Price], subject to adjustment in accordance with Article 2 below
		
	Class of Stock:	  	Common Stock of the Company, par value $0.0001 per share (the “Common Stock”)
		
	Warrant Price:	  	[lower of (i) the average closing price for the ten (10) trading days ending the day before the Issue Date, or (ii) the closing price on the day before the Issue Date]
		
	Issue Date:	  	[Date]
		
	Expiration Date:	  	The 5th anniversary after the Issue Date
		
	Credit Facility:	  	This Warrant is issued in connection with the Loan and Security Agreement dated as of October 18, 2011 among Oxford Finance LLC, as Lender and Collateral Agent, the Lenders from time to time party thereto, including Silicon Valley
Bank, Horizon Technology Finance Corporation, and the Company (as amended from time to time, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, including, without limitation, the mutual
promises contained in the Loan Agreement, OXFORD FINANCE LLC (“Oxford;” together with any registered holder from time to time of this Warrant or any holder of the shares issuable or issued upon exercise of this Warrant, “Holder”)
is entitled to purchase the number of fully paid and nonassessable shares of Common Stock (the “Shares”) at the Warrant Price, all as set forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and
upon the terms and conditions set forth in this Warrant. 
 ARTICLE 1. EXERCISE. 

1.1 Method of Exercise. Holder may exercise this Warrant in whole or in part by delivering a duly executed Notice of Exercise in
substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to an account
designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 

1.2 Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1, Holder may from time to time convert this
Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares
by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3. 

 1.3 Fair Market Value. The fair market value of each Share shall be the closing price of a
share of Common Stock reported on the NASDAQ Capital Market for the business day immediately before Holder delivers its Notice of Exercise to the Company. 

1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this Warrant and, if applicable, the Company
receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant exercisable for the number of
shares of Common Stock remaining available for purchase under this Warrant. 
 1.5 Replacement of Warrants. On receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or,
in the case of mutilation on surrender and cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 

1.6 Treatment of Warrant Upon Acquisition of Company. 

1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale, license, or other disposition
of all or substantially all of the assets of the Company, or any reorganization, consolidation, or merger of the Company where the holders of the Company’s securities immediately before the transaction beneficially own less than 50% of the
outstanding voting securities of the surviving entity immediately after the transaction. 
 1.6.2 Treatment of Warrant at
Acquisition. 
 A) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is not an asset sale and in which
the consideration is cash, Marketable Securities, or a combination thereof, either (a) Holder shall exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of
such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will expire upon the consummation of such Acquisition. The Company shall provide the Holder with written notice of its request relating to the foregoing
(together with such reasonable information as the Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the
proposed Acquisition. 
 B) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is an “arms length”
sale of all or substantially all of the Company’s assets (and only its assets) to a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”), either (a) Holder shall exercise its conversion or
purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will continue until the Expiration Date if
the Company continues as a going concern following the closing of any such True Asset Sale. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder
may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

 C) Upon the closing of any Acquisition other than those particularly described in subsections (A) and
(B) above, the successor entity shall assume this Warrant, and shall succeed to, and be substituted for (so that from and after the date of such Acquisition, the provisions of this Warrant referring to the “Company” shall refer
instead to the successor entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such successor entity had been named as the Company herein.
Upon the closing of the Acquisition, this Warrant shall be exercisable for, in lieu of the Shares, the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if
such Shares were outstanding on the record date of such Acquisition and subsequent closing. The Warrant Price and/or number and type of securities subject to this Warrant following such Acquisition shall be adjusted accordingly (as determined in
good faith by the Board of Directors of the Company). 
 As used herein (x) “Affiliate” shall mean any person or entity that owns or controls
directly or indirectly ten (10) percent or more of the Common Stock, any person or entity that controls or is controlled by or is under common control with such persons or entities, and each of such person’s or entity’s officers,
directors, joint venturers or partners, as applicable; and (y) “Marketable Securities” shall mean securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of
Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act;
(ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise or convert this Warrant on or prior to the closing thereof is then traded on a
national securities exchange or over-the-counter market; (iii) Holder would not be restricted by contract or by applicable federal or state securities laws from publicly re-selling, within six (6) months following the closing of such
Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to convert this Warrant pursuant to Section 1.2 above in full on or prior to the closing of such Acquisition;
and (iv) the issuer has a market capitalization, as of the date immediately prior to and on the closing of such Acquisition of at least $200,000,000. 

ARTICLE 2. ADJUSTMENTS TO THE SHARES. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its Common Stock payable in shares of Common Stock, or
other securities of the Company, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares
of record as of the date the dividend occurred. If the Company subdivides the shares of Common Stock by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and
the Warrant Price shall be proportionately decreased. If the outstanding shares of Common Stock are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and
the number of Shares shall be proportionately decreased. Any adjustment made pursuant to the first sentence of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend, and any adjustment pursuant to the second and third sentences of this paragraph shall become effective immediately after the effective date of such subdivision or combination. 

 2.2 Reclassification, Exchange, Combinations or Substitution. Upon any changes in the
Common Stock by reason of recapitalizations, reclassifications, exchanges, substitutions, combinations, reorganizations, liquidations or similar transactions, or other event that results in a change of the number and/or class of the securities
issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had
been exercised immediately before such event. The Company or its successor shall promptly issue to Holder an amendment to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or conversion of
this Warrant as a result of such reclassification, exchange, substitution or other event that results in a change of the number and/or class of securities issuable upon exercise or conversion of this Warrant. The amendment to this Warrant shall
provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable
upon exercise of the new Warrant. The provisions of this Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 

2.3 Intentionally Omitted. 

2.4 No Impairment. The Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of
assets, consolidation, merger, dissolution, issuance, or sale of its securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company,
but shall at all times in good faith assist in carrying out of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article against impairment. 

2.5 Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of this Warrant and the number of Shares to
be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount computed by
multiplying the fractional interest by the fair market value of a full Share. 
 2.6 Certificate as to Adjustments. Upon each
adjustment of the Warrant Price, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such
adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant
Price. 
 ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants and covenants to the Holder as follows: All Shares which may be
issued upon the exercise of the purchase right represented by this Warrant, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided
for herein or under applicable federal and state securities laws. 

 3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any
dividend or distribution upon any of its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to effect any reclassification or recapitalization of any of its stock; or (c) to merge
or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder: (1) at
least 10 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of Common Stock will be entitled thereto) or for determining rights
to vote, if any, in respect of the matters referred to in (a) above; (2) in the case of the matters referred to in (b) and (c) above at least 10 days prior written notice of the date when the same will take place (and specifying
the date on which the holders of common stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such event). Notwithstanding the foregoing, the failure to deliver such notice or any
defect therein shall not affect the validity of the corporate action required to be described in such notice. Company will also provide information requested by Holder reasonably necessary to enable the Holder to comply with the Holder’s
accounting or reporting requirements. 
 3.3 Reserved. 

3.4 No Shareholder Rights. Except as provided in this Warrant, the Holder will not have any rights as a shareholder of the Company
until the exercise of this Warrant. 
 ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents and warrants to the Company as
follows: 
 4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by the Holder
will be acquired for investment for the Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Securities Act of 1933, as amended (the “Act”). Holder also
represents that the Holder has not been formed for the specific purpose of acquiring this Warrant or the Shares. 
 4.2 Disclosure of
Information. The Holder has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. The
Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the
Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to the Holder or to which the Holder has access. 

4.3 Investment Experience. The Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. The Holder has experience as an investor in securities of companies in the development stage and acknowledges that the Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has
such knowledge and experience in financial or business matters that the Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship
with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables the Holder to be aware of the character, business acumen and financial circumstances of such persons. 

 4.4 Accredited Investor Status. The Holder is an “accredited investor” within
the meaning of Regulation D promulgated under the Act. 
 4.5 The Act. The Holder understands that this Warrant and the Shares
issuable upon exercise or conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as
expressed herein. The Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or
unless exemption from such registration and qualification are otherwise available. 
 ARTICLE 5. MISCELLANEOUS. 

5.1 Term. This Warrant is exercisable in whole or in part at any time and from time to time on or before the Expiration Date. 

5.2 Legends. This Warrant and the Shares shall be imprinted with a legend in substantially the following form: 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW
OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant may not be
transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal
opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to any “affiliate” (as such term is defined in Regulation D
promulgated under the Act) of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no
material question as to the availability of current information as referenced in Rule 144(c), Holder represents that it has complied with Rule 144(d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule
144(f), and the Company is provided with a copy of Holder’s notice of proposed sale. 
 5.4 Transfer Procedure. After receipt by
Holder of the executed Warrant, Oxford may transfer all or part of this Warrant to one or more of Oxford’s affiliates (each, an “Oxford Affiliate, by execution of an Assignment substantially in the form of Appendix 2. Subject

 
to the provisions of Article 5.3 and upon providing the Company with written notice, Oxford, any such Oxford Affiliate and any subsequent Holder may transfer all or part of this Warrant or the
Shares issuable upon exercise of this Warrant to any transferee, provided, however, in connection with any such transfer, the Oxford Affiliate(s) or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred
with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). 

5.5 Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and
effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may (or on the first business day after transmission by
facsimile) be, in writing by the Company or such Holder from time to time. Effective upon receipt of the fully executed Warrant and the initial transfer described in Article 5.4 above, all notices to the Holder shall be addressed as follows until
the Company receives notice of a change of address in connection with a transfer or otherwise: 
 Oxford Finance LLC 

133 N. Fairfax Street 

Alexandria, VA 22314 
 Attn: Tim
A. Lex, Chief Operating Officer 
 Telephone: (703) 519-4900 

Facsimile: (703) 519-5225 
 Notice to the
Company shall be addressed as follows until the Holder receives notice of a change in address: 
 SUNESIS PHARMACEUTICALS, INC. 

395 Oyster Point Boulevard, Suite 400 

South San Francisco, California 94080 

Attn: Chief Financial Officer 

Telephone: (650) 266-3717 

Facsimile: (650) 266-3505 

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8 Automatic Conversion upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other
security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be converted
pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised or converted, and the Company shall promptly deliver a certificate representing the Shares (or such other
securities) issued upon such conversion to the Holder. 

 5.9 Counterparts. This Warrant may be executed in counterparts, all of which together
shall constitute one and the same agreement. 
 5.10 Governing Law. This Warrant shall be governed by and construed in accordance
with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 
 [Balance of Page
Intentionally Left Blank] 

									
		 		 		 	Dated as of the Issue Date indicated above.
				
	“COMPANY”	 		 		 	
				
	SUNESIS PHARMACEUTICALS, INC.	 		 		 	
					
	By:	 	  
	 		 	By:	 	  

					
	Name:	 	  
	 		 	Name:	 	  

					
	Title:	 		 		 	Title:	 	  

		
	HOLDER”	 	
		
	OXFORD FINANCE LLC	 	
					
	By:	 	  
	 		 		 	
					
	Name:	 	  
	 		 		 	
		 	(Print)	 		 		 	
	Title:	 	  
	 		 		 	

 APPENDIX 1 

NOTICE OF EXERCISE 

1. Holder elects to purchase                  shares of the
common stock of SUNESIS PHARMACEUTICALS, INC., par value $0.0001 per share (the “Common Stock”), pursuant to the terms of the attached Warrant, and tenders payment of the purchase price of the shares in full. 

[or] 
 2. Holder elects to convert the attached
Warrant into shares of Common Stock in the manner specified in the Warrant. This conversion is exercised for                  of the Shares covered by the Warrant. 

[Strike paragraph that does not apply.] 
 3.
Please issue a certificate or certificates representing the shares of Common Stock in the name specified below: 
  

					
	  
	 		 	
	 Holders Name
	 		 	
			
	  
	 		 	
			
	  
	 		 	
	 (Address)
	 		 	

 4. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Article 4 of the Warrant as the date hereof. 
 HOLDER: 

 

			
	  

		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	(Date):	 	  

 APPENDIX 2 

ASSIGNMENT 
 For
value received, Oxford Finance LLC hereby sells, assigns and transfers unto 
  

					
	Name:	  	[OXFORD TRANSFEREE]	  	
			
	Address:	  	  
	  	
			
	Tax ID:	  	  
	  	

 that certain Warrant to Purchase Stock issued by SUNESIS PHARMACEUTICALS, INC. (the “Company”), on
[Date] (the “Warrant”) together with all rights, title and interest therein. 
  

			
	OXFORD FINANCE LLC
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

  

			
	Date:	 	  

 By its execution below, and for the benefit of the Company, [OXFORD TRANSFEREE] makes each of the representations and
warranties set forth in Article 4 of the Warrant and agrees to all other provisions of the Warrant as of the date hereof. 
  

			
	[OXFORD TRANSFEREE]
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT
AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

WARRANT TO PURCHASE STOCK 
  

			
	Company:	  	SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”)
		
	Number of Shares:	  	[$5,000/Warrant Price], subject to adjustment in accordance with Article 2 below
		
	Class of Stock:	  	Common Stock of the Company, par value $0.0001 per share (the “Common Stock”)
		
	Warrant Price:	  	[lower of (i) the average closing price for the ten (10) trading days ending the day before the Issue Date, or (ii) the closing price on the day before the Issue Date]
		
	Issue Date:	  	[Date]
		
	Expiration Date:	  	The 5th anniversary after the Issue Date
		
	Credit Facility:	  	This Warrant is issued in connection with the Loan and Security Agreement dated as of October 18, 2011 among Oxford Finance LLC, as Lender and Collateral Agent, the Lenders from time to time party thereto, including Silicon Valley
Bank, Horizon Technology Finance Corporation, and the Company (as amended from time to time, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, including, without limitation, the mutual
promises contained in the Loan Agreement, SILICON VALLEY BANK (“Bank;” together with any registered holder from time to time of this Warrant or any holder of the shares issuable or issued upon exercise of this Warrant, “Holder”)
is entitled to purchase the number of fully paid and nonassessable shares of Common Stock (the “Shares”) at the Warrant Price, all as set forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and
upon the terms and conditions set forth in this Warrant. 
 ARTICLE 1. EXERCISE. 

1.1 Method of Exercise. Holder may exercise this Warrant in whole or in part by delivering a duly executed Notice of Exercise in
substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to an account
designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 

1.2 Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1, Holder may from time to time convert this
Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares
by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3. 

 1.3 Fair Market Value. The fair market value of each Share shall be the closing price of a
share of Common Stock reported on the NASDAQ Capital Market for the business day immediately before Holder delivers its Notice of Exercise to the Company. 

1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this Warrant and, if applicable, the Company
receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant exercisable for the number of
shares of Common Stock remaining available for purchase under this Warrant. 
 1.5 Replacement of Warrants. On receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or,
in the case of mutilation on surrender and cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 

1.6 Treatment of Warrant Upon Acquisition of Company. 

1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale, license, or other disposition
of all or substantially all of the assets of the Company, or any reorganization, consolidation, or merger of the Company where the holders of the Company’s securities immediately before the transaction beneficially own less than 50% of the
outstanding voting securities of the surviving entity immediately after the transaction. 
 1.6.2 Treatment of Warrant at
Acquisition. 
 A) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is not an asset sale and in which
the consideration is cash, Marketable Securities, or a combination thereof, either (a) Holder shall exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of
such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will expire upon the consummation of such Acquisition. The Company shall provide the Holder with written notice of its request relating to the foregoing
(together with such reasonable information as the Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the
proposed Acquisition. 
 B) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is an “arms length”
sale of all or substantially all of the Company’s assets (and only its assets) to a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”), either (a) Holder shall exercise its conversion or
purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will continue until the Expiration Date if
the Company continues as a going concern following the closing of any such True Asset Sale. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder
may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

 C) Upon the closing of any Acquisition other than those particularly described in subsections (A) and
(B) above, the successor entity shall assume this Warrant, and shall succeed to, and be substituted for (so that from and after the date of such Acquisition, the provisions of this Warrant referring to the “Company” shall refer
instead to the successor entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such successor entity had been named as the Company herein.
Upon the closing of the Acquisition, this Warrant shall be exercisable for, in lieu of the Shares, the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if
such Shares were outstanding on the record date of such Acquisition and subsequent closing. The Warrant Price and/or number and type of securities subject to this Warrant following such Acquisition shall be adjusted accordingly (as determined in
good faith by the Board of Directors of the Company). 
 As used herein (x) “Affiliate” shall mean any person or entity that owns or controls
directly or indirectly ten (10) percent or more of the Common Stock, any person or entity that controls or is controlled by or is under common control with such persons or entities, and each of such person’s or entity’s officers,
directors, joint venturers or partners, as applicable; and (y) “Marketable Securities” shall mean securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of
Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act;
(ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise or convert this Warrant on or prior to the closing thereof is then traded on a
national securities exchange or over-the-counter market; (iii) Holder would not be restricted by contract or by applicable federal or state securities laws from publicly re-selling, within six (6) months following the closing of such
Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to convert this Warrant pursuant to Section 1.2 above in full on or prior to the closing of such Acquisition;
and (iv) the issuer has a market capitalization, as of the date immediately prior to and on the closing of such Acquisition of at least $200,000,000. 

ARTICLE 2. ADJUSTMENTS TO THE SHARES. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its Common Stock payable in shares of Common Stock, or
other securities of the Company, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares
of record as of the date the dividend occurred. If the Company subdivides the shares of Common Stock by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and
the Warrant Price shall be proportionately decreased. If the outstanding shares of Common Stock are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and
the number of Shares shall be proportionately decreased. Any adjustment made pursuant to the first sentence of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend, and any adjustment pursuant to the second and third sentences of this paragraph shall become effective immediately after the effective date of such subdivision or combination. 

 2.2 Reclassification, Exchange, Combinations or Substitution. Upon any changes in the
Common Stock by reason of recapitalizations, reclassifications, exchanges, substitutions, combinations, reorganizations, liquidations or similar transactions, or other event that results in a change of the number and/or class of the securities
issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had
been exercised immediately before such event. The Company or its successor shall promptly issue to Holder an amendment to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or conversion of
this Warrant as a result of such reclassification, exchange, substitution or other event that results in a change of the number and/or class of securities issuable upon exercise or conversion of this Warrant. The amendment to this Warrant shall
provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable
upon exercise of the new Warrant. The provisions of this Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 

2.3 Intentionally Omitted. 

2.4 No Impairment. The Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of
assets, consolidation, merger, dissolution, issuance, or sale of its securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company,
but shall at all times in good faith assist in carrying out of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article against impairment. 

2.5 Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of this Warrant and the number of Shares to
be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount computed by
multiplying the fractional interest by the fair market value of a full Share. 
 2.6 Certificate as to Adjustments. Upon each
adjustment of the Warrant Price, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such
adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant
Price. 
 ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants and covenants to the Holder as follows: All Shares which may be
issued upon the exercise of the purchase right represented by this Warrant, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided
for herein or under applicable federal and state securities laws. 

 3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any
dividend or distribution upon any of its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to effect any reclassification or recapitalization of any of its stock; or (c) to merge
or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder: (1) at
least 10 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of Common Stock will be entitled thereto) or for determining rights
to vote, if any, in respect of the matters referred to in (a) above; (2) in the case of the matters referred to in (b) and (c) above at least 10 days prior written notice of the date when the same will take place (and specifying
the date on which the holders of common stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such event). Notwithstanding the foregoing, the failure to deliver such notice or any
defect therein shall not affect the validity of the corporate action required to be described in such notice. Company will also provide information requested by Holder reasonably necessary to enable the Holder to comply with the Holder’s
accounting or reporting requirements. 
 3.3 Reserved. 

3.4 No Shareholder Rights. Except as provided in this Warrant, the Holder will not have any rights as a shareholder of the Company
until the exercise of this Warrant. 
 ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents and warrants to the Company as
follows: 
 4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by the Holder
will be acquired for investment for the Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Securities Act of 1933, as amended (the “Act”). Holder also
represents that the Holder has not been formed for the specific purpose of acquiring this Warrant or the Shares. 
 4.2 Disclosure of
Information. The Holder has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. The
Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the
Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to the Holder or to which the Holder has access. 

4.3 Investment Experience. The Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. The Holder has experience as an investor in securities of companies in the development stage and acknowledges that the Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has
such knowledge and experience in financial or business matters that the Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship
with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables the Holder to be aware of the character, business acumen and financial circumstances of such persons. 

 4.4 Accredited Investor Status. The Holder is an “accredited investor” within
the meaning of Regulation D promulgated under the Act. 
 4.5 The Act. The Holder understands that this Warrant and the Shares
issuable upon exercise or conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as
expressed herein. The Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or
unless exemption from such registration and qualification are otherwise available. 
 ARTICLE 5. MISCELLANEOUS. 

5.1 Term. This Warrant is exercisable in whole or in part at any time and from time to time on or before the Expiration Date. 

5.2 Legends. This Warrant and the Shares shall be imprinted with a legend in substantially the following form: 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW
OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant may not be
transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal
opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to any “affiliate” (as such term is defined in Regulation D
promulgated under the Act) including but not limited to SVB Financial Group (formerly Silicon Valley Bancshares)), or any other affiliate of Bank, provided that any such transferee is an “accredited investor” as defined in Regulation D
promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of current information as referenced in Rule 144(c), Holder represents that it has complied
with Rule 144(d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule 144(f), and the Company is provided with a copy of Holder’s notice of proposed sale. 

5.4 Transfer Procedure. After receipt by Holder of the executed Warrant, Bank will transfer all of this Warrant to Holder’s parent
company, SVB Financial Group, by 

 
execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of Article 5.3 and upon providing the Company with written notice, SVB Financial Group and any
subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant to any transferee, provided, however, in connection with any such transfer, SVB Financial Group or any subsequent Holder will give the
Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if
applicable). 
 5.5 Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed
delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may (or on the first business day after
transmission by facsimile) be, in writing by the Company or such Holder from time to time. Effective upon receipt of the fully executed Warrant and the initial transfer described in Article 5.4 above, all notices to the Holder shall be addressed as
follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 
 SVB Financial Group 

Attn: Treasury Department 
 3003
Tasman Drive, HA 200 
 Santa Clara, CA 95054 

Telephone: 408-654-7400 

Facsimile: 408-496-2405 
 Notice to the Company
shall be addressed as follows until the Holder receives notice of a change in address: 
 SUNESIS PHARMACEUTICALS, INC. 

395 Oyster Point Boulevard, Suite 400 

South San Francisco, California 94080 

Attn: Chief Financial Officer 

Telephone: (650) 266-3717 

Facsimile: (650) 266-3505 

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8 Automatic Conversion upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other
security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be converted
pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised or converted, and the Company shall promptly deliver a certificate representing the Shares (or such other
securities) issued upon such conversion to the Holder. 

 5.9 Counterparts. This Warrant may be executed in counterparts, all of which together
shall constitute one and the same agreement. 
 5.10 Governing Law. This Warrant shall be governed by and construed in accordance
with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 
 [Balance of Page
Intentionally Left Blank] 

			
		 	
	
	“COMPANY”
	
	SUNESIS PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

	
	“HOLDER”
	
	SILICON VALLEY BANK
		
	By:	 	  

		
	Name:	 	  

		 	(Print)
	Title:	 	  

 

			
		 	Dated as of the Issue Date indicated above.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

 

 APPENDIX 1 

NOTICE OF EXERCISE 

1. Holder elects to purchase                  shares of the
common stock of SUNESIS PHARMACEUTICALS, INC., par value $0.0001 per share (the “Common Stock”), pursuant to the terms of the attached Warrant, and tenders payment of the purchase price of the shares in full. 

[or] 
 2. Holder elects to convert the attached
Warrant into shares of Common Stock in the manner specified in the Warrant. This conversion is exercised for                  of the Shares covered by the Warrant. 

[Strike paragraph that does not apply.] 
 3.
Please issue a certificate or certificates representing the shares of Common Stock in the name specified below: 
  

					
	  
	 		 	
	 Holders Name
	 		 	
			
	  
	 		 	
			
	  
	 		 	
	 (Address)
	 		 	

 4. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Article 4 of the Warrant as the date hereof. 
 HOLDER: 

 

			
	  

		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	(Date):	 	  

 APPENDIX 2 

ASSIGNMENT 
 For
value received, Silicon Valley Bank hereby sells, assigns and transfers unto 
  

			
	Name:	  	SVB Financial Group
	Address:	  	3003 Tasman Drive (HA-200)
		  	Santa Clara, CA 95054
		
	Tax ID:	  	91-1962278

 that certain Warrant to Purchase Stock issued by SUNESIS PHARMACEUTICALS, INC. (the “Company”), on
[Date] (the “Warrant”) together with all rights, title and interest therein. 
  

			
	SILICON VALLEY BANK
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

  

			
	Date:	 	  

 By its execution below, and for the benefit of the Company, SVB Financial Group makes each of the representations and
warranties set forth in Article 4 of the Warrant and agrees to all other provisions of the Warrant as of the date hereof. 
  

			
	SVB FINANCIAL GROUP
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT
AND APPLICABLE STATE SECURITIES LAW OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

WARRANT TO PURCHASE STOCK 
  

			
	Company:	  	SUNESIS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”)
		
	Number of Shares:	  	[$5,000/Warrant Price], subject to adjustment in accordance with Article 2 below
		
	Class of Stock:	  	Common Stock of the Company, par value $0.0001 per share (the “Common Stock”)
		
	Warrant Price:	  	[lower of (i) the average closing price for the ten (10) trading days ending the day before the Issue Date, or (ii) the closing price on the day before the Issue Date]
		
	Issue Date:	  	[Date]
		
	Expiration Date:	  	The 5th anniversary after the Issue Date
		
	Credit Facility:	  	This Warrant is issued in connection with the Loan and Security Agreement dated as of October 18, 2011 among Oxford Finance LLC, as Lender and Collateral Agent, the Lenders from time to time party thereto, including Silicon Valley
Bank, Horizon Technology Finance Corporation, and the Company (as amended from time to time, the “Loan Agreement”).

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, including, without limitation, the mutual
promises contained in the Loan Agreement, HORIZON TECHNOLOGY FINANCE CORPORATION (“HRZN;” together with any registered holder from time to time of this Warrant or any holder of the shares issuable or issued upon exercise of this Warrant,
“Holder”) is entitled to purchase the number of fully paid and nonassessable shares of Common Stock (the “Shares”) at the Warrant Price, all as set forth above and as adjusted pursuant to Article 2 of this Warrant, subject
to the provisions and upon the terms and conditions set forth in this Warrant. 
 ARTICLE 1. EXERCISE. 

1.1 Method of Exercise. Holder may exercise this Warrant in whole or in part by delivering a duly executed Notice of Exercise in
substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth in Article 1.2, Holder shall also deliver to the Company a check, wire transfer (to an account
designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased. 

1.2 Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1, Holder may from time to time convert this
Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this Warrant minus the aggregate Warrant Price of such Shares
by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3. 

 1.3 Fair Market Value. The fair market value of each Share shall be the closing price of a
share of Common Stock reported on the NASDAQ Capital Market for the business day immediately before Holder delivers its Notice of Exercise to the Company. 

1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this Warrant and, if applicable, the Company
receives payment of the aggregate Warrant Price, the Company shall deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant exercisable for the number of
shares of Common Stock remaining available for purchase under this Warrant. 
 1.5 Replacement of Warrants. On receipt of evidence
reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or,
in the case of mutilation on surrender and cancellation of this Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 

1.6 Treatment of Warrant Upon Acquisition of Company. 

1.6.1 “Acquisition”. For the purpose of this Warrant, “Acquisition” means any sale, license, or other disposition
of all or substantially all of the assets of the Company, or any reorganization, consolidation, or merger of the Company where the holders of the Company’s securities immediately before the transaction beneficially own less than 50% of the
outstanding voting securities of the surviving entity immediately after the transaction. 
 1.6.2 Treatment of Warrant at Acquisition. 

A) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is not an asset sale and in which the consideration is
cash, Marketable Securities, or a combination thereof, either (a) Holder shall exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or
(b) if Holder elects not to exercise the Warrant, this Warrant will expire upon the consummation of such Acquisition. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such
reasonable information as the Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

B) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is an “arms length” sale of all or substantially
all of the Company’s assets (and only its assets) to a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”), either (a) Holder shall exercise its conversion or purchase right under this
Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will continue until the Expiration Date if the Company continues as a
going concern following the closing of any such True Asset Sale. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder may request in connection
with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

 C) Upon the closing of any Acquisition other than those particularly described in subsections (A) and
(B) above, the successor entity shall assume this Warrant, and shall succeed to, and be substituted for (so that from and after the date of such Acquisition, the provisions of this Warrant referring to the “Company” shall refer
instead to the successor entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such successor entity had been named as the Company herein.
Upon the closing of the Acquisition, this Warrant shall be exercisable for, in lieu of the Shares, the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the unexercised portion of this Warrant as if
such Shares were outstanding on the record date of such Acquisition and subsequent closing. The Warrant Price and/or number and type of securities subject to this Warrant following such Acquisition shall be adjusted accordingly (as determined in
good faith by the Board of Directors of the Company). 
 As used herein (x) “Affiliate” shall mean any person or entity that owns or controls
directly or indirectly ten (10) percent or more of the Common Stock, any person or entity that controls or is controlled by or is under common control with such persons or entities, and each of such person’s or entity’s officers,
directors, joint venturers or partners, as applicable; and (y) “Marketable Securities” shall mean securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of
Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act;
(ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the Acquisition were Holder to exercise or convert this Warrant on or prior to the closing thereof is then traded on a
national securities exchange or over-the-counter market; (iii) Holder would not be restricted by contract or by applicable federal or state securities laws from publicly re-selling, within six (6) months following the closing of such
Acquisition, all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to convert this Warrant pursuant to Section 1.2 above in full on or prior to the closing of such Acquisition;
and (iv) the issuer has a market capitalization, as of the date immediately prior to and on the closing of such Acquisition of at least $200,000,000. 

ARTICLE 2. ADJUSTMENTS TO THE SHARES. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on its Common Stock payable in shares of Common Stock, or
other securities of the Company, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the Shares
of record as of the date the dividend occurred. If the Company subdivides the shares of Common Stock by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and
the Warrant Price shall be proportionately decreased. If the outstanding shares of Common Stock are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and
the number of Shares shall be proportionately decreased. Any adjustment made pursuant to the first sentence of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such
dividend, and any adjustment pursuant to the second and third sentences of this paragraph shall become effective immediately after the effective date of such subdivision or combination. 

 2.2 Reclassification, Exchange, Combinations or Substitution. Upon any changes in the
Common Stock by reason of recapitalizations, reclassifications, exchanges, substitutions, combinations, reorganizations, liquidations or similar transactions, or other event that results in a change of the number and/or class of the securities
issuable upon exercise or conversion of this Warrant, Holder shall be entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had
been exercised immediately before such event. The Company or its successor shall promptly issue to Holder an amendment to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or conversion of
this Warrant as a result of such reclassification, exchange, substitution or other event that results in a change of the number and/or class of securities issuable upon exercise or conversion of this Warrant. The amendment to this Warrant shall
provide for adjustments which shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable
upon exercise of the new Warrant. The provisions of this Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 

2.3 Intentionally Omitted. 

2.4 No Impairment. The Company shall not, by amendment of its Certificate of Incorporation or through a reorganization, transfer of
assets, consolidation, merger, dissolution, issuance, or sale of its securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed under this Warrant by the Company,
but shall at all times in good faith assist in carrying out of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to protect Holder’s rights under this Article against impairment. 

2.5 Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of this Warrant and the number of Shares to
be issued shall be rounded down to the nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount computed by
multiplying the fractional interest by the fair market value of a full Share. 
 2.6 Certificate as to Adjustments. Upon each
adjustment of the Warrant Price, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such
adjustment and the facts upon which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant
Price. 
 ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants and covenants to the Holder as follows: All Shares which may be
issued upon the exercise of the purchase right represented by this Warrant, shall, upon issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens and encumbrances except for restrictions on transfer provided
for herein or under applicable federal and state securities laws. 

 3.2 Notice of Certain Events. If the Company proposes at any time (a) to declare any
dividend or distribution upon any of its stock, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to effect any reclassification or recapitalization of any of its stock; or (c) to merge
or consolidate with or into any other corporation, or sell, lease, license, or convey all or substantially all of its assets, or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder: (1) at
least 10 days prior written notice of the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of Common Stock will be entitled thereto) or for determining rights
to vote, if any, in respect of the matters referred to in (a) above; (2) in the case of the matters referred to in (b) and (c) above at least 10 days prior written notice of the date when the same will take place (and specifying
the date on which the holders of common stock will be entitled to exchange their common stock for securities or other property deliverable upon the occurrence of such event). Notwithstanding the foregoing, the failure to deliver such notice or any
defect therein shall not affect the validity of the corporate action required to be described in such notice. Company will also provide information requested by Holder reasonably necessary to enable the Holder to comply with the Holder’s
accounting or reporting requirements. 
 3.3 Reserved. 

3.4 No Shareholder Rights. Except as provided in this Warrant, the Holder will not have any rights as a shareholder of the Company
until the exercise of this Warrant. 
 ARTICLE 4. REPRESENTATIONS, WARRANTIES OF THE HOLDER. The Holder represents and warrants to the Company as
follows: 
 4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by the Holder
will be acquired for investment for the Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Securities Act of 1933, as amended (the “Act”). Holder also
represents that the Holder has not been formed for the specific purpose of acquiring this Warrant or the Shares. 
 4.2 Disclosure of
Information. The Holder has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. The
Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the
Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to the Holder or to which the Holder has access. 

4.3 Investment Experience. The Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. The Holder has experience as an investor in securities of companies in the development stage and acknowledges that the Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has
such knowledge and experience in financial or business matters that the Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship
with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables the Holder to be aware of the character, business acumen and financial circumstances of such persons. 

 4.4 Accredited Investor Status. The Holder is an “accredited investor” within
the meaning of Regulation D promulgated under the Act. 
 4.5 The Act. The Holder understands that this Warrant and the Shares
issuable upon exercise or conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as
expressed herein. The Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or
unless exemption from such registration and qualification are otherwise available. 
 ARTICLE 5. MISCELLANEOUS. 

5.1 Term. This Warrant is exercisable in whole or in part at any time and from time to time on or before the Expiration Date. 

5.2 Legends. This Warrant and the Shares shall be imprinted with a legend in substantially the following form: 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW
OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

5.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant may not be
transferred or assigned in whole or in part without compliance with applicable federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal
opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel if the transfer is to any “affiliate” (as such term is defined in Regulation D
promulgated under the Act) of Holder, provided that any such transferee is an “accredited investor” as defined in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is no
material question as to the availability of current information as referenced in Rule 144(c), Holder represents that it has complied with Rule 144(d) and (e) in reasonable detail, the selling broker represents that it has complied with Rule
144(f), and the Company is provided with a copy of Holder’s notice of proposed sale. 
 5.4 Transfer Procedure. After receipt by
Holder of the executed Warrant, HRZN may transfer all or part of this Warrant to one or more of HRZN’s affiliates (each, an “HRZN Affiliate”), by execution of an Assignment substantially in the form of Appendix 2.

 
Subject to the provisions of Article 5.3 and upon providing the Company with written notice, HRZN, any such HRZN Affiliate and any subsequent Holder may transfer all or part of this Warrant or
the Shares issuable upon exercise of this Warrant to any transferee, provided, however, in connection with any such transfer, the HRZN Affiliate(s) or any subsequent Holder will give the Company notice of the portion of the Warrant being transferred
with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). 

5.5 Notices. All notices and other communications from the Company to the Holder, or vice versa, shall be deemed delivered and
effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address as may have been furnished to the Company or the Holder, as the case may (or on the first business day after transmission by
facsimile) be, in writing by the Company or such Holder from time to time. Effective upon receipt of the fully executed Warrant and the initial transfer described in Article 5.4 above, all notices to the Holder shall be addressed as follows until
the Company receives notice of a change of address in connection with a transfer or otherwise: 
 Horizon Technology Finance Corporation

 312 Farmington Avenue 

Farmington, Connecticut 06032 

Attn: Legal Department 

Telephone: (860) 676-8657 

Facsimile: (860) 676-8655 
 Notice to the
Company shall be addressed as follows until the Holder receives notice of a change in address: 
 SUNESIS PHARMACEUTICALS, INC. 

395 Oyster Point Boulevard, Suite 400 

South San Francisco, California 94080 

Attn: Chief Financial Officer 

Telephone: (650) 266-3717 

Facsimile: (650) 266-3505 

5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular
instance and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7 Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8 Automatic Conversion upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other
security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be converted
pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised or converted, and the Company shall promptly deliver a certificate representing the Shares (or such other
securities) issued upon such conversion to the Holder. 

 5.9 Counterparts. This Warrant may be executed in counterparts, all of which together
shall constitute one and the same agreement. 
 5.10 Governing Law. This Warrant shall be governed by and construed in accordance
with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 
 [Balance of Page
Intentionally Left Blank] 

			
		 	
	
	“COMPANY”
	
	SUNESIS PHARMACEUTICALS, INC.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

	
	“HOLDER”
	
	HORIZON TECHNOLOGY FINANCE CORPORATION
		
	By:	 	  

		
	Name:	 	  

		 	(Print)
	Title:	 	  

 

			
		 	Dated as of the Issue Date indicated above.
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

 
 

 APPENDIX 1 

NOTICE OF EXERCISE 

1. Holder elects to purchase                  shares of the
common stock of SUNESIS PHARMACEUTICALS, INC., par value $0.0001 per share (the “Common Stock”), pursuant to the terms of the attached Warrant, and tenders payment of the purchase price of the shares in full. 

[or] 
 2. Holder elects to convert the attached
Warrant into shares of Common Stock in the manner specified in the Warrant. This conversion is exercised for                  of the Shares covered by the Warrant. 

[Strike paragraph that does not apply.] 
 3.
Please issue a certificate or certificates representing the shares of Common Stock in the name specified below: 
  

					
	  
	  		  	
	 Holders Name
	  		  	
			
	  
	  		  	
			
	  
	  		  	
	 (Address)
	  		  	

 4. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Article 4 of the Warrant as the date hereof. 
 HOLDER: 

 

			
	  

		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

		
	(Date):	 	  

 APPENDIX 2 

ASSIGNMENT 
 For
value received, Horizon Technology Finance Corporation hereby sells, assigns and transfers unto 
  

					
	Name:	  	[HRZN TRANSFEREE]	  	
			
	Address:	  	  
	  	
			
	Tax ID:	  	  
	  	

 that certain Warrant to Purchase Stock issued by SUNESIS PHARMACEUTICALS, INC. (the “Company”), on
[Date] (the “Warrant”) together with all rights, title and interest therein. 
  

			
	HORIZON TECHNOLOGY FINANCE CORPORATION
		
	By:	 	  

		
	Name:	 	  

		
	Title:	 	  

  

			
	Date:	 	  

 By its execution below, and for the benefit of the Company, [HRZN TRANSFEREE] makes each of the representations and warranties
set forth in Article 4 of the Warrant and agrees to all other provisions of the Warrant as of the date hereof. 
  

			
	[HRZN TRANSFEREE]
		
	By:	 	  

		
	Name:	 	  

		
	Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]